Endo Pharmaceuticals will return global rights to Urocidin to Bioniche Life Sciences. Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. Urocidin is formulated for the treatment of bladder cancer In November 2012, a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer being run by Endo was discontinued. The trial, a randomized, active-control...